Brent R Stockwell

This inventor holds 25 USPTO granted patents and 16 published patent applications and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Columbia University, Combinatorx, Incorporated, Whitehead Institute for Biomedical Research. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brent R Stockwell. Retrieved from https://idiyas.com/inventor/brent-r-stockwell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 16)

% Patents Active = 36.0

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 2.7

ph-index = 5

Forward Citations = 201(Granted Patents)

Location History:

Boston, MA (US) (2002 - 2006)
New York, NY (US) (2008 - 2021)

Company Filing History:

Combinatorx, Incorporated

patents

4 out of 318

Whitehead Institute for Biomedical Research

Massachusetts Institute of Technology

patents

6. 2 out of 4

Prolexys Pharmaceuticals, Inc.

patents

7. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Ferroptosis

Cancer Therapy

Neoplastic Disorders

RAS Inhibitors

Alzheimer's Disease

Small Molecule Compounds

Endoplasmic Reticulum Stress

Tumor Agents

Combinatorial Libraries

Genotype-Selective

Cell Death Assays

Oncogenic Compounds

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12377107 - NT5C2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia (2025-08-05),

2. 12227500 - Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress (2025-02-18),

3. 11192849 - Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders (2021-12-07),

4. 10947188 - Small molecule ferroptosis inducers (2021-03-16),

5. 10597381 - Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders (2020-03-24),

6. 10259775 - Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders (2019-04-16),

7. 10233171 - Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders (2019-03-19),

8. 9938245 - Carbonyl erastin analogs and their use (2018-04-10),

9. 9926293 - Multivalent RAS binding compounds (2018-03-27),

10. 9695133 - Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use (2017-07-04),

11. 9580398 - Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders (2017-02-28),

12. 8546421 - Oncogenic-RAS-signal dependent lethal compounds (2013-10-01),

13. 8535897 - Assays for non-apoptotic cell death and uses thereof (2013-09-17),

14. 8518959 - Quinoxaline derivatives as antitumor agents (2013-08-27),

15. 8124365 - Identification of genotype-selective anti-tumor agents (2012-02-28),

Title: Brent R. Stockwell: Innovator in Neurodegenerative Disease Research

Introduction

Brent R. Stockwell is a notable inventor based in New York, NY, with an impressive portfolio of 24 patents. His work primarily focuses on developing therapeutic compounds aimed at addressing challenges related to toxic stress in cells and neurodegenerative diseases. Through his innovative research, he seeks to make significant contributions to the fields of pharmacology and molecular medicine.

Latest Patents

Among Stockwell's latest patents is the invention titled "Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress." This invention provides compounds designed to mitigate the toxicity from endoplasmic reticulum (ER) stress, along with compositions for medical treatments. Additionally, he has patented methods for treating disorders and neurodegenerative diseases linked to axon degeneration.

Another significant patent is for "Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders." This patent introduces a compound structure aimed at modulating ferroptosis—a type of regulated cell death—and reducing reactive oxygen species (ROS) in cells, crucial for treating excitotoxic disorders and neurodegenerative conditions.

Career Highlights

Brent R. Stockwell has held prestigious positions at renowned institutions such as Columbia University in the City of New York, where he has contributed significantly to research efforts in pharmacology and biotechnology. Additionally, he worked with Combinatorx, Incorporated, where his insights into drug development led to innovative therapeutic solutions.

Collaborations

Throughout his career, Stockwell has collaborated with several notable researchers, including Rachid Skouta and Scott E. Dixon. These collaborations have facilitated cross-disciplinary approaches to tackling complex medical challenges, enhancing the impact of their combined research efforts.

Conclusion

Brent R. Stockwell's innovative spirit and dedicated research efforts in the field of neurodegenerative disease treatment underscore his importance as an inventor. His patents exemplify forward-thinking advancements in medicinal chemistry, paving the way for future research and potential therapies that could significantly improve patient outcomes in the face of neurodegenerative conditions.

Profile summary based on public USPTO records.